Nuvalent (NUVL) Common Equity (2020 - 2026)
Nuvalent's (NUVL) quarterly Common Equity came in at $1.2 billion in Q1 2026, up 16.15% YoY from $1.0 billion in Q1 2025, and down 5.93% on a QoQ basis from $1.2 billion in Q4 2025.
Nuvalent (NUVL) Common Equity (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Common Equity data on file, last reported at $1.2 billion in Q1 2026.
- Quarterly Common Equity rose 16.15% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 16.15% YoY) and the FY2025 annual result came in at $1.2 billion, up 16.69% from the prior year.
- Common Equity retreated to $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.2 billion in Q4 2025 to a low of $236.6 million in Q3 2022.
- A 5-year average of $700.3 million and a median of $675.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 796.22% — and 2025, when it decreased 24.59%.
- Tracing NUVL's Common Equity over 5 years: stood at $463.0 million in 2022, then surged by 51.32% to $700.6 million in 2023, then jumped by 52.71% to $1.1 billion in 2024, then grew by 16.69% to $1.2 billion in 2025, then dropped by 5.93% to $1.2 billion in 2026.
- The last three Common Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $845.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | 845.40 Mn |
| Jun 30, 2025 | 939.74 Mn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.07 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 637.04 Mn |
| Mar 31, 2024 | 675.04 Mn |
| Dec 31, 2023 | 700.56 Mn |
| Sep 30, 2023 | 395.98 Mn |
| Jun 30, 2023 | 421.15 Mn |
| Mar 31, 2023 | 443.97 Mn |
| Dec 31, 2022 | 462.98 Mn |
| Sep 30, 2022 | 236.58 Mn |
| Jun 30, 2022 | 252.99 Mn |
| Mar 31, 2022 | 268.92 Mn |
| Dec 31, 2021 | 285.04 Mn |
| Sep 30, 2021 | 301.13 Mn |
| Jun 30, 2021 | -47.74 Mn |